Please note that following on from information received from the company, NICE has decided to suspend this evaluation from its current work programme. The timelines for this evaluation are to be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this evaluation will be available in due course.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1410 |
Project Team
| Project lead | Daniel Davies |
Email enquiries
- If you have any queries please email TATeam3@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 13 June 2023 | Suspended. Please note that following on from information received from the company, NICE has decided to suspend this evaluation from its current work programme. The timelines for this evaluation are to be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this evaluation will be available in due course. |
| 07 February 2023 | Invitation to participate |
| 07 November 2022 - 07 December 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 05 July 2022 | Please note that following on from advice received from the company this evaluation has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the evaluation will begin during late November 2022 when we will write to you about how you can get involved. |
| 11 May 2022 | Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course. |
| 21 June 2021 - 02 July 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 21 June 2021 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators: 21 June to 2 July 2021. |
| 01 September 2020 | In progress. Topic is in progress |
| 01 September 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of lenadogene nolparvovec for treating Leber hereditary optic neuropathy. Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course. |
| 25 September 2018 - 23 October 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual